Two Sigma Investments LP Trims Holdings in Rezolute, Inc. (NASDAQ:RZLT)

Two Sigma Investments LP trimmed its position in Rezolute, Inc. (NASDAQ:RZLT) by 16.9% in the 4th quarter, HoldingsChannel reports. The firm owned 59,463 shares of the company’s stock after selling 12,118 shares during the quarter. Two Sigma Investments LP’s holdings in Rezolute were worth $291,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. raised its position in Rezolute by 48.5% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock valued at $97,000 after acquiring an additional 6,470 shares in the last quarter. Point72 Europe London LLP purchased a new position in Rezolute during the fourth quarter valued at approximately $720,000. Man Group plc purchased a new position in Rezolute during the fourth quarter valued at approximately $425,000. OMERS ADMINISTRATION Corp purchased a new position in Rezolute during the fourth quarter valued at approximately $372,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Rezolute by 19.8% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,223 shares of the company’s stock valued at $2,578,000 after acquiring an additional 86,990 shares in the last quarter. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Price Performance

Rezolute stock opened at $4.39 on Wednesday. The stock has a market capitalization of $375.43 million, a PE ratio of -3.60 and a beta of 1.04. Rezolute, Inc. has a 12 month low of $2.22 and a 12 month high of $6.19. The business has a 50 day simple moving average of $3.56 and a 200-day simple moving average of $4.15.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). On average, equities research analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Nevan C. Elam purchased 12,302 shares of the company’s stock in a transaction that occurred on Thursday, March 27th. The stock was purchased at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the transaction, the chief executive officer now owns 224,119 shares of the company’s stock, valued at $638,739.15. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Daron Evans purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average price of $2.89 per share, with a total value of $28,900.00. Following the completion of the transaction, the chief financial officer now directly owns 237,900 shares of the company’s stock, valued at $687,531. This represents a 4.39% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 29,060 shares of company stock worth $83,694. 18.39% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RZLT. Wall Street Zen cut Rezolute from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Wedbush restated an “outperform” rating and issued a $12.00 price objective on shares of Rezolute in a research report on Wednesday, May 14th. HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research report on Monday, April 28th. Finally, JMP Securities boosted their price objective on Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.83.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.